MENOPAUSAL hormone therapy (MHT) is not associated with an increased risk of death, according to a Danish study of over 800,000 women published last week.
Researchers used nationwide Danish registers to track women born between 1950 and 1977, and followed them for a median of 14 years from the age of 45.
After controlling for health and demographic factors that may have influenced outcomes, they found no increased risk of death from taking MHT.
There was also some evidence suggesting that transdermal MHT had a slightly lower risk of death compared to no treatment.
Endocrinologist Professor Susan Davis, from Monash University, urged caution in reading too much into the results, pointing out that the general duration of use was brief, at a median 1.7 years.
"So would we expect MHT use for an average of less than two years to cause harm?" she said - read the research HERE.
The above article was sent to subscribers in Pharmacy Daily's issue from 23 Feb 26
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 23 Feb 26
